Trial · NCT01435018
Outcomes45
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 45
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2016. | Cumulative events per 100 persons | NUMBER |
| PRIMARY | Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2018. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of Death by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2016. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of Death by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2018. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of IERC-confirmed KS Progression by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2016. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of IERC-confirmed KS Progression by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2018. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of AIDS-defining Event by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2016. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of AIDS-defining Event by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2018. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2016. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2018. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART | From study entry to week 12 | All eligible participants who initiated study chemotherapy with available data as of March 2016. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART | From study entry to week 12 | All eligible participants who initiated study chemotherapy with available data as of March 2018. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2016. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2018. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2016. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2018. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2016. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2018. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of Change in KS Treatment by Week 48 for ET+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2016. | Cumulative events per 100 persons | NUMBER |
| SECONDARY | Cumulative Rate of Change in KS Treatment by Week 48 for BV+ART vs. PTX+ART | From study entry to week 48 | All eligible participants who initiated study chemotherapy with available data as of March 2018. | Cumulative events per 100 persons | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01435018/outcomes